Primary Antibodies

  1. Quick-Filters:
  2. Cited (53)
  3. Highly Validated (8)

Items 1 to 20 of 71 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

BETVIA allergen Bet v1 antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G27E9B1 Purified Pollen E, IP
50 µg / €440.00
  Dendritics SAS

BETVIA allergen Bet v1 antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G27E9B1 Purified Pollen E, IP
0.1 mg / €590.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG3 H.G26F6B2.06 Purified Pollen E
50 µg / €440.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG3 H.G26F6B2.06 Purified Pollen E
0.1 mg / €590.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G11A9F3.03 Purified Pollen E
50 µg / €440.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G11A9F3.03 Purified Pollen E
0.1 mg / €590.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G28C10.01 Purified Pollen E
50 µg / €440.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G28C10.01 Purified Pollen E
0.1 mg / €590.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG1 H.G5F2A4.09 Purified Pollen E, FN, WB
50 µg / €440.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG1 H.G5F2A4.09 Purified Pollen E, WB
0.1 mg / €590.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G3A3C2.04 Purified Pollen E
50 µg / €440.00
  Dendritics SAS

BETVIA antibody

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G3A3C2.04 Purified Pollen E
0.1 mg / €590.00
  Dendritics SAS

CD49b / ITGA2 antibody

CD49b / ITGA2 Human IgG1 B4F12 Alexa Fluor 488 Hu F, ICC/IF
50 µg / €520.00
  Dendritics SAS

CD49b / ITGA2 antibody

CD49b / ITGA2 Human IgG1 B4F12 Alexa Fluor 488 Hu F, ICC/IF
0.1 mg / €710.00
  Dendritics SAS

CD49b / ITGA2 antibody

CD49b / ITGA2 Human IgG1 B4F12 Alexa Fluor 647 Hu F, ICC/IF
50 µg / €520.00
  Dendritics SAS

CD49b / ITGA2 antibody

CD49b / ITGA2 Human IgG1 B4F12 Alexa Fluor 647 Hu F, ICC/IF
0.1 mg / €710.00
  Dendritics SAS

CD49b / ITGA2 antibody

CD49b / ITGA2 Human IgG1 B4F12 Biotin Hu E, F
50 µg / €490.00
  Dendritics SAS

CD49b / ITGA2 antibody

CD49b / ITGA2 Human IgG1 B4F12 Biotin Hu E, F
0.1 mg / €670.00
  Dendritics SAS

CD49b / ITGA2 antibody

IF staining of human platelets with B4F12 Human IgG1 B4F12 Purified Hu E, F, ICC/IF
50 µg / €440.00
  Dendritics SAS

CD49b / ITGA2 antibody

IF staining of human platelets with B4F12 Human IgG1 B4F12 Purified Hu E, F, ICC/IF
0.1 mg / €590.00
  Dendritics SAS

Items 1 to 20 of 71 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  • LinkedIn